Hagop Kantarjian
Hagop Kantarjian is a hematologist and oncologist specializing in leukemia. He is a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he holds the Samsung Distinguished Leukemia Chair in Cancer Medicine. Provided by Wikipedia
Showing 1 - 6 results of 6 for search 'Hagop Kantarjian', query time: 0.01s
Refine Results
-
1
PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes by Alexandre Bazinet, Alex Bataller, Guillermo Montalban-Bravo, Kelly Chien, Koji Sasaki, Wei Ying Jen, Mahesh Swaminathan, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Published 2025-07-01Get full text
Article -
2
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab by Nicholas J. Short, Hagop Kantarjian, Ken Furudate, Nitin Jain, Farhad Ravandi, Omer Karrar, Sanam Loghavi, Lewis Nasr, Fadi G. Haddad, Jayastu Senapati, Rebecca Garris, Koichi Takahashi, Elias Jabbour
Published 2025-05-01Get full text
Article -
3
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell... by Roberta S. Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G. Haddad, Alexis Geppner, Ghayas C. Issa, Koji Sasaki, Jayastu Senapati, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia
Published 2025-06-01Get full text
Article -
4
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. by Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernan Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A Zweidler-McKay, Dario Campana, Gautam Borthakur, Carlos Bueso-Ramos, Elizabeth Shpall, Deborah A Thomas, Craig T Jordan, Hagop Kantarjian, William R Wilson, Richard Lock, Michael Andreeff, Marina Konopleva
Published 2011-01-01Get full text
Article -
5
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase... by Mahesh Swaminathan, Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Navel G. Daver, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Nicholas J. Short, William G. Wierda, Nitin Jain, Steven M. Kornblau, Lucia Masarova, Sherry A. Pierce, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Y. Konopleva
Published 2025-04-01Get full text
Article -
6
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients by Christophe Willekens, Alexandre Bazinet, Samy Chraibi, Alex Bataller, Justine Decroocq, Naszrin Arani, Benjamin Carpentier, Caitlin Rausch, Delphine Lebon, Abhishek Maiti, Nicolas Gauthier, Nicholas Short, Sarah Bonnet, Koji Sasaki, Sabine Khalife-Hachem, Mahesh Swaminathan, Jean-Baptiste Micol, Florence Pasquier, Christophe Marzac, Damien Roos-Weil, Laurent Pascal, Naval Daver, Tapan Kadia, Didier Bouscary, Farhad Ravandi, Arnaud Pages, Hagop Kantarjian, Stéphane De Botton, Courtney DiNardo
Published 2025-04-01Get full text
Article